Eagle Asset Management Inc. boosted its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 1.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,635,140 shares of the biotechnology company’s stock after acquiring an additional 30,688 shares during the quarter. Eagle Asset Management Inc.’s holdings in Atara Biotherapeutics were worth $23,088,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Atara Biotherapeutics by 59.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,010 shares during the period. Aperio Group LLC purchased a new position in Atara Biotherapeutics during the 2nd quarter valued at $63,000. Bank of Montreal Can boosted its holdings in Atara Biotherapeutics by 81.1% during the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 3,723 shares during the period. Oppenheimer & Co. Inc. boosted its holdings in Atara Biotherapeutics by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 12,682 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 2,550 shares during the period. Finally, Virtus ETF Advisers LLC purchased a new position in Atara Biotherapeutics during the 2nd quarter valued at $245,000. Institutional investors own 91.98% of the company’s stock.

In related news, insider Joe Newell sold 3,500 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $13.51, for a total transaction of $47,285.00. Following the transaction, the insider now directly owns 57,998 shares of the company’s stock, valued at approximately $783,552.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.00% of the company’s stock.

A number of research firms recently issued reports on ATRA. Citigroup set a $14.00 price objective on Atara Biotherapeutics and gave the company a “hold” rating in a report on Monday, August 12th. ValuEngine upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Mizuho set a $43.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a report on Wednesday, September 18th. Jefferies Financial Group cut Atara Biotherapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the company from $32.00 to $15.00 in a report on Monday, September 16th. Finally, Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $28.89.

NASDAQ ATRA traded down $0.12 on Friday, reaching $13.40. 545,300 shares of the stock traded hands, compared to its average volume of 677,343. The company has a fifty day moving average price of $13.16 and a 200-day moving average price of $18.16. Atara Biotherapeutics Inc has a 12 month low of $10.38 and a 12 month high of $43.94. The company has a market cap of $679.50 million, a price-to-earnings ratio of -2.54 and a beta of 2.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.80 and a current ratio of 7.80.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.40) by $0.09. As a group, research analysts anticipate that Atara Biotherapeutics Inc will post -5.71 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.